The increasing government and non-government awareness-raising initiatives, reducing cost of genetic testing and high prevalence of Huntington’s disease (HD), and presence of a large middle-aged population are some of the major factors propelling the growth of the global Huntington’s disease genetic testing market. As a result of these factors, the industry is expected to generate $28.3 million revenue by 2030, witnessing a CAGR of 3.1% during the forecast period (2020–2030).
The COVID-19 pandemic has negatively impacted the global Huntington’s disease genetic testing market. Due to COVID-19, hospitals have delayed these services to protect people from the virus and save medical equipment and supplies for those who do need them the most, which is why healthcare professionals of all stripes have been pulled into coronavirus duty. The market is expected to grow with the uplifting of the bans and resumption of commercial activities.
Adult Category To Dominate Worldwide Market during Forecast Period
On the basis of patient group, the worldwide Huntington’s disease genetic testing market is classified into adult, aged, adolescent, and child. Among these, the adult category is expected to lead the market in the coming years. It would mainly be due to the high number of people under this age group across the world, who account for a significant volume of genetic tests. Moreover, HD is more prevalent in people under this age group, which leads to their dominance, globally.
Furthermore, on the basis of patient gender, the Huntington’s disease genetic testing market is classified into male and female. Of these categories, the male category generated the higher revenue during the historical period (2014–2019), and it is further projected to advance at the higher CAGR during the forecast period. This would mainly be on account of the higher prevalence of HD among the male population, especially adults and the aged, across the world.
Geographically, North America dominated the global Huntington’s disease genetic testing market during the historical period. The region is further expected to continue this trend during the forecast period, mainly on account of the high prevalence of HD, rising geriatric population, and increasing awareness about the disease and genetic testing services among the people, owing to the initiatives by public and private entities, especially in the U.S. The market in the region is further expected to advance at the highest rate owing to the reducing cost of genetic tests.
Product Launch Is Major Strategic Measure Taken by Players
Players in the Huntington’s disease genetic testing industry are launching various products and services in order to enhance their offerings portfolio and improve their market position. For instance, in February 2020, CaGaT GmbH launched CeGaT Exome Xtra, a genetic diagnostic tool for patients with complex, unspecific, and rare diseases.
Furthermore, Asuragen Inc., a company that offers genetic testing services, announced the commercialization of the AmplideX Huntington (HTT) kit, which detects cytosine–adenine–guanine (CAG) trinucleotide repeats within the HTT gene, in January 2019. This has helped in increasing the product offerings of the company.
Some of the major players in the Huntington’s disease genetic testing market are Laboratory Corporation of America Holdings, Quest Diagnostics Inc., EGL Genetic Diagnostics LLC, CooperGenomics Inc., Blueprint Genetics Oy, CeGaT GmbH, Centogene N.V., Variantyx Inc., and Asuragen Inc.